# Bio-Solid Phase Extraction / Tandem Mass Spectrometry for Identification of Bioactive Compounds in Mixtures

Erica M. Forsberg	and Jo	hn D.	Brennan*
-------------------	--------	-------	----------

Biointerfaces Institute and Department of Chemistry & Chemical Biology, McMaster University, 1280

Main St. West, Hamilton, ON, L8S 4L8

\*Author to whom correspondence should be addressed

Tel: (905) 525-9140 (ext. 20682)

E-mail: brennanj@mcmaster.ca

Internet: brennanlab.ca

#### SUPPLEMENTARY EXPERIMENTAL SECTION

Column Leaching. Eluate from 10 cm column segments were collected in 15  $\mu$ L fractions, mixed with a 10  $\mu$ L aliquot of 100  $\mu$ M adenosine and allowed to react for 5 minutes. The reaction was quenched with 75  $\mu$ L of methanol followed by injection into an AB Sciex QTrap API 2000. The resulting solutions were analyzed in multiple reaction monitoring (MRM) mode for adenosine (268  $\rightarrow$  136 m/z) and inosine (269  $\rightarrow$  137 m/z) signal ratios and compared to a calibration curve to determine the amount of enzyme leached from the column.

Column Characterization by Michaelis Menten Kinetics. Column activity was assessed on entrapped ADA columns by injecting increasing concentrations of adenosine up to 500  $\mu$ M via an Eksigent AS-1 autosampler coupled to the ADA column and then connected to the ESI source. The flow rate was 5  $\mu$ L/min and was teed prior to the source to a makeup flow of 1% acetic acid in LCMS grade methanol at a rate of 5  $\mu$ L/min. Calibration curves were prepared via a previously described method to correct for the  $^{13}$ C isotope of adenosine interfering with the inosine MRM transition.

Column Characterization by bioSPE. Entrapped ADA columns were used to determine the protein loading by infusing EHNA at increasing concentrations from 10 nM to 2  $\mu$ M. The columns were washed with 8 bed volumes of 20 mM ammonium acetate prior to elution with 3% acetic acid. The resulting peaks were quantified by use of an EHNA calibration curve prepared in 3% acetic acid. Extracted peaks were plotted versus the infused concentration to determine the maximal loaded concentration and dissociation constants by fitting data to one-site saturation ligand binding using SigmaPlot 10.0.

**Mass Spectrometer Settings.** Instrument settings for IMER assays were as follow: curtain gas = 45.0, collision gas = medium, ion spray voltage = 5500V, temperature = 200 °C, declustering potential = 45 V,

exit potential = 11 V, collision energy = 26 V, cell exit potential = 3.0 for both the adenosine and inosine MRM transitions. Conditions for compounds used in bioSPE assays are provided in Table S1.

Entrapped ADA Column Optimization. Sol-gel entrapped ADA columns were tested with a simple mixture containing EHNA, fluorescein and huperzine A at concentrations ranging from 10 nM to 2  $\mu$ M. Mixtures were loaded onto the column using an 85  $\mu$ L injection loop, washed with 200 mM ammonium acetate pH 7.5, then eluted with either 50% methanol or 3% acetic acid. Competitive displacement of EHNA was also assessed using either 25  $\mu$ M or 100  $\mu$ M adenosine.

Column Characterization by FAC. Protein binding sites ( $B_T$  in picomoles) were quantified using frontal affinity chromatography-tandem mass spectrometry<sup>2</sup> (FAC-MS/MS) by running increasing concentrations of EHNA, from 1 to 10  $\mu$ M, through a series of columns (using a fresh column for each ligand concentration) and fitting the data to Equation (1):

$$V - V_o = \frac{B_T}{[A] + K_d} \tag{1}$$

where  $V_0$  is the void volume ( $\mu$ L), V is the retention volume ( $\mu$ L), [A] is the concentration of EHNA ( $\mu$ M), and  $K_D$  is the binding constant of the ligand to the protein ( $\mu$ M). The retention volume was determined as the volume where the frontal curve reached 50% of the maximum intensity. Columns with entrapped protein had too small a protein concentration to provide observable shifts in elution volume relative to the void volume, and instead had protein loading calculated by measuring the relative turnover of adenosine to inosine as compared to columns with covalently bound proteins.

The covalently bound ADA columns were assessed for reproducibility by performing replicate extractions of EHNA on a single ADA column. Columns were loaded with 85 µL of a simple ternary

mixture containing 1  $\mu$ M each of EHNA, fluorescein and trimethoprim, then washed with 200 mM ammonium acetate pH 7.5 for 10 column bed volumes, followed by elution with 3% acetic acid. A calibration curve was generated using EHNA in 3% acetic acid from 50 nM to 10  $\mu$ M in order to quantify the amount of EHNA extracted from the column. Replicate injections of the mixture were assessed for reproducibility by measuring the EHNA XIC area extracted from the same column.

#### SUPPLEMENTARY RESULTS & DISCUSSION

Column Leaching and Activity. Leaching of the enzyme from the column was observed for the first 8 bed volumes when flushing at 5  $\mu$ L/min (Figure S1A). The amount of enzyme lost on each column is negligible after this volume and was therefore used as a minimum conditioning procedure prior to using. Without adequate conditioning, PEG and glycerol appear to suppress enzyme function, which is partially due to the microviscosity they impart in the silica matrix that interferes with the pressure driven diffusion of analytes into the mesopores and hence contact with the enzyme, as well as interfering with MS detection by causing ion suppression of analytes of interest. Once conditioned, the Michealis-Menten constant was determined to be  $20 \pm 7 \mu$ M (Figure S1B). This is within error of the solution value of  $24 \mu$ M $^3$  and a higher affinity compared to our previous report on ADA activity on column of  $100 \mu$ M.\frac{1}{2} Enzyme reactor mode is a beneficial way of running initial kinetic studies of the target biomolecule since it does not subject it to a harsh wash and can be used repeatedly for hundreds of injections without inhibiting function.\frac{4}{2}

**Entrapped ADA Column Optimization.** ADA columns produced via sol-gel entrapment of the enzyme were tested for their ability to extract EHNA from a simple mixture containing EHNA, fluorescein and huperzine A. Figure S2A shows that both 50% methanol and 3% acetic acid were capable of effectively separating EHNA from fluorescein and huperzine A. A competitive extraction assay was also performed using adenosine as the elution solvent to confirm the presence of an active site

inhibitor versus an allosteric inhibitor (Figure S2B). An increase in substrate concentration during elution shows an increase in EHNA signal. However, adenosine does not provide a signal enhancement of EHNA as with 50% methanol or 3% acetic acid. Ion suppression from the high substrate concentrations used coupled with the slow off-rate of EHNA contributes to reduced signal enhancement and elongated peak widths. Successive extractions could not be performed on the entrapped ADA columns without a significant loss of activity, eventually leading to a complete loss of activity after 4 repeated extractions. Once mixture complexity was increased on the columns, the separation efficiency of the columns decreased, leading to incomplete extraction of EHNA versus non-specific binders. Initial bioSPE proof of concept and optimization studies using columns with entrapped ADA did not provide a reproducible elution peak during the harsh washing step, which was determined to be the result of inadequate protein loading. All subsequent bioSPE assays used columns with covalently bound ADA, which produced a much higher number of binding sites (see Results section). Unfortunately, when the entrapped ADA columns were tested with a 20-component EHNA spiked mixture, an extremely low amount of EHNA was extracted. The reason for this was found to be that the amount of protein in the column was only  $1.42 \pm 0.04$  pmol, based on peak areas for EHNA extracted from entrapped ADA columns using 3% acetic acid as compared to the peak area obtained from a column with covalently bound ADA (see Figure S2 and compare to Figure 5). In addition, protein leaching from the macroporous silica matrix resulted in a continually decreasing and irreproducible protein concentration on the columns. This effect, coupled with interfering signals from PEG and glycerol byproducts remaining from column fabrication, caused a significant decrease in inhibitor retention and increased detection limits, making both frontal affinity chromatography (FAC) and bioSPE unfeasible using entrapped ADA columns.

Covalent Column Characterization by Frontal Affinity Chromatography (FAC). The protein loading (B<sub>T</sub>) of covalently-bound ADA columns was assessed by FAC using EHNA infused as

concentrations ranging from 1 to 10 µM. In cases where the signal could not reach a 100% signal intensity compared to infusion on a heat denatured ADA column, the maximum signal intensity on the heat denatured column was used as 100% signal intensity to calculate the percent infusion for the signal on the functional ADA column. The retention volume at 50% infusion of EHNA on the ADA column was plotted versus EHNA concentration and fitted to equation (1) using Sigma Plot 10.0 software. The column protein loading was characterized via FAC since specific activity was extremely high and the maximum turnover velocity  $(V_{max})$  could not be reached prior to running into ESI-MS ion suppression effects, thus leading to difficulties in determining  $K_{\rm M}$ . An observed 25 minute frontal retention for 10  $\mu$ M EHNA was used as a starting point for determining  $B_T$  and  $K_D$  by FAC. Figure S3A shows increased retention volumes with decreasing EHNA concentration and when fitting the data to equation 1 in Figure S3B, the protein loading  $(B_T)$  was determined to be  $712 \pm 17$  pmol. dissociation constant ( $K_D$ ) was not reliably determined by the FAC method ( $25 \pm 27$  nM), as the amount of functional protein was very high compared to the actual  $K_D$ , leading to relatively high error upon curve fitting. Covalent columns were therefore chosen to perform all further bioSPE experiments since they were better at producing higher signal with less interferences with a higher reproducibility.

**Column Reproducibility.** Figure S4 shows the reproducibility of EHNA extraction from covalently bound ADA columns. The RSD was 8.8% for 8 replicate extractions with no significant loss in extracted EHNA area over the day tested. This indicates that columns can be reused multiple times for extraction without adversely affecting ADA activity.

## **Supplemental Tables & Figures**

Table S1. MRM transitions for bioactive compounds in screening mixture

Compound ID   Q1   Q3   (msec)   (V)   (
N5-butyl-1,2,4-thiadiazole-3,5-diamine
N5-butyl-1,2,4-thiadiazole-3,5-diamine
diamine
nicotinohydrazide         179.2         90         500         68         10         41         2.5           3,8-dithia-1,6-diazaspiro[4.4]nona-1,6-diene-2,7-diamine         189.1         113.1         500         39         10         21         3           1-[(3-pyridylamino)methyl] pyrrolidine-2,5-dione         206.2         107         500         30         10         30         3           epibatidine         208.9         126.1         500         62         11         32         3           1-{[(6-methyl-2-pyridyl)amino]methyl} pyrrolidine-2,5-dione         220.1         121.2         500         31         8         23         3           2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine         231.2         192.2         500         45         10         27         3           huperzine A         243.2         226.2         500         62         11         30         4           N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine         248.2         180.2         500         35         9         20         3           Pyrimethamine         249.2         177.1         500         83         11         39         4           N-{2-[[(acetoxy)imino](amino) methyl]-3-fluoroph
3,8-dithia-1,6-diazaspiro[4.4]nona-1,6-diene-2,7-diamine
diene-2,7-diamine   189.1   113.1   500   39   10   21   3     1-[(3-pyridylamino)methyl]   206.2   107   500   30   10   30   3     epibatidine   208.9   126.1   500   62   11   32   3     1-{[(6-methyl-2-pyridyl)amino]methyl} pyrrolidine-2,5-dione   220.1   121.2   500   31   8   23   3     2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine   231.2   192.2   500   45   10   27   3     huperzine A   243.2   226.2   500   62   11   30   4     N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine   248.2   180.2   500   35   9   20   3     pyrimethamine   249.2   177.1   500   83   11   39   4     N-{2-[[(acetoxy)imino](amino)   methyl]-3-fluorophenyl}acetamide   254.2   152.2   500   65   10   30   3     methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate   267.2   180.1   500   45   8   27   3     tubercidin   267.2   135.1   500   50   11   27   3
1-[(3-pyridylamino)methyl] pyrrolidine-2,5-dione 206.2 107 500 30 10 30 3  epibatidine 208.9 126.1 500 62 11 32 3  1-{[(6-methyl-2- pyridyl)amino]methyl} pyrrolidine- 2,5-dione 220.1 121.2 500 31 8 23 3  2-[2-(2-propyn-1-ylsulfanyl)phenyl]- 1,4,5,6-tetrahydropyrimidine 231.2 192.2 500 45 10 27 3  huperzine A 243.2 226.2 500 62 11 30 4  N2-[3-(1H-imidazol-1-yl)propyl]-3- nitropyridin-2-amine 248.2 180.2 500 35 9 20 3  pyrimethamine 249.2 177.1 500 83 11 39 4  N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide 254.2 152.2 500 32 9 16 3  vidarabine 268.2 136.1 500 65 10 30 3  methyl-N-(4-methoxyphenyl)-4- morpholinecarimidothioate 267.2 180.1 500 45 8 27 3  tubercidin 267.2 135.1 500 50 11 27 3
Description
epibatidine         208.9         126.1         500         62         11         32         3           1-{[(6-methyl-2-pyridyl)amino]methyl} pyrrolidine-2,5-dione         220.1         121.2         500         31         8         23         3           2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine         231.2         192.2         500         45         10         27         3           huperzine A         243.2         226.2         500         62         11         30         4           N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine         248.2         180.2         500         35         9         20         3           pyrimethamine         249.2         177.1         500         83         11         39         4           N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide         254.2         152.2         500         32         9         16         3           vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2
1-{[(6-methyl-2-pyridyl)amino]methyl} pyrrolidine-2,5-dione         2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine       231.2       192.2       500       45       10       27       3         huperzine A       243.2       226.2       500       62       11       30       4         N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine       248.2       180.2       500       35       9       20       3         pyrimethamine       249.2       177.1       500       83       11       39       4         N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide       254.2       152.2       500       32       9       16       3         vidarabine       268.2       136.1       500       65       10       30       3         methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate       267.2       180.1       500       45       8       27       3         tubercidin       267.2       135.1       500       50       11       27       3
pyridyl)amino]methyl} pyrrolidine- 2,5-dione  220.1 121.2 500 31 8 23 3  2-[2-(2-propyn-1-ylsulfanyl)phenyl]- 1,4,5,6-tetrahydropyrimidine 231.2 192.2 500 45 10 27 3  huperzine A  243.2 226.2 500 62 11 30 4  N2-[3-(1H-imidazol-1-yl)propyl]-3- nitropyridin-2-amine 248.2 180.2 500 35 9 20 3  pyrimethamine 249.2 177.1 500 83 11 39 4  N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide 254.2 152.2 500 32 9 16 3  vidarabine 268.2 136.1 500 65 10 30 3  methyl-N-(4-methoxyphenyl)-4- morpholinecarimidothioate 267.2 180.1 500 45 8 27 3  tubercidin 267.2 135.1 500 50 11 27 3
2,5-dione       220.1       121.2       500       31       8       23       3         2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine       231.2       192.2       500       45       10       27       3         huperzine A       243.2       226.2       500       62       11       30       4         N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine       248.2       180.2       500       35       9       20       3         pyrimethamine       249.2       177.1       500       83       11       39       4         N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide       254.2       152.2       500       32       9       16       3         vidarabine       268.2       136.1       500       65       10       30       3         methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate       267.2       180.1       500       45       8       27       3         tubercidin       267.2       135.1       500       50       11       27       3
2,5-dione       220.1       121.2       500       31       8       23       3         2-[2-(2-propyn-1-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine       231.2       192.2       500       45       10       27       3         huperzine A       243.2       226.2       500       62       11       30       4         N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine       248.2       180.2       500       35       9       20       3         pyrimethamine       249.2       177.1       500       83       11       39       4         N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide       254.2       152.2       500       32       9       16       3         vidarabine       268.2       136.1       500       65       10       30       3         methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate       267.2       180.1       500       45       8       27       3         tubercidin       267.2       135.1       500       50       11       27       3
1,4,5,6-tetrahydropyrimidine       231.2       192.2       500       45       10       27       3         huperzine A       243.2       226.2       500       62       11       30       4         N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine       248.2       180.2       500       35       9       20       3         pyrimethamine       249.2       177.1       500       83       11       39       4         N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide       254.2       152.2       500       32       9       16       3         vidarabine       268.2       136.1       500       65       10       30       3         methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate       267.2       180.1       500       45       8       27       3         tubercidin       267.2       135.1       500       50       11       27       3
1,4,5,6-tetrahydropyrimidine       231.2       192.2       500       45       10       27       3         huperzine A       243.2       226.2       500       62       11       30       4         N2-[3-(1H-imidazol-1-yl)propyl]-3-nitropyridin-2-amine       248.2       180.2       500       35       9       20       3         pyrimethamine       249.2       177.1       500       83       11       39       4         N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide       254.2       152.2       500       32       9       16       3         vidarabine       268.2       136.1       500       65       10       30       3         methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate       267.2       180.1       500       45       8       27       3         tubercidin       267.2       135.1       500       50       11       27       3
N2-[3-(1H-imidazol-1-yl)propyl]-3- nitropyridin-2-amine         248.2         180.2         500         35         9         20         3           pyrimethamine         249.2         177.1         500         83         11         39         4           N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide         254.2         152.2         500         32         9         16         3           vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4- morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
N2-[3-(1H-imidazol-1-yl)propyl]-3- nitropyridin-2-amine         248.2         180.2         500         35         9         20         3           pyrimethamine         249.2         177.1         500         83         11         39         4           N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide         254.2         152.2         500         32         9         16         3           vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4- morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
nitropyridin-2-amine         248.2         180.2         500         35         9         20         3           pyrimethamine         249.2         177.1         500         83         11         39         4           N-{2-[[(acetoxy)imino](amino)         254.2         152.2         500         32         9         16         3           vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
N-{2-[[(acetoxy)imino](amino) methyl]-3-fluorophenyl}acetamide 254.2 152.2 500 32 9 16 3 vidarabine 268.2 136.1 500 65 10 30 3 methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate 267.2 180.1 500 45 8 27 3 tubercidin 267.2 135.1 500 50 11 27 3
methyl]-3-fluorophenyl}acetamide         254.2         152.2         500         32         9         16         3           vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
vidarabine         268.2         136.1         500         65         10         30         3           methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
methyl-N-(4-methoxyphenyl)-4-morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
morpholinecarimidothioate         267.2         180.1         500         45         8         27         3           tubercidin         267.2         135.1         500         50         11         27         3
2-(4-chlorophenyl)-2-oxoethyl-N,N-
dimethylcarbamodithioate 274.1 88.1 500 27 8 28 3
sanguinine 274.3 199 500 65 11 32 3
(erythro-9-(2-hydroxy-3-
nonyl)adenine)   278.2   136.1   500   68   10   30   3
galanthamine 288 213.1 500 65 11 31 3
trimethoprim 291.2 230 500 80 10 33 3
N'-(2,6-
dimethoxybenzoyl)nicotinohydrazide 302.2 165.2 500 30 10 30 3
N-[2-(diethylamino)ethyl]-2,3,4,5,6-
pentamethylbenzenesulfonamide 327.3 100.2 500 60 11 31 2
6-{[3-(dimethylamino)propyl]amino}-
2-morpholino-3-nitrobenzonitrile 334.3 230.2 500 42 10 27 3.5




Figure S1. (A) Leaching of adenosine deaminase from a 10 cm sol-gel entrapped ADA column. Eight bed volumes are sufficient for removing leachable protein as a way of pre-conditioning the column prior to use. (B) Enzyme activity versus adenosine concentration on entrapped ADA columns shows a  $K_{\rm M}$  value of  $20 \pm 7~\mu{\rm M}$ , as determined by fitting the data to a Lineweaver-Burke model.




Figure S2. (A) Extraction of simple mixture from sol-gel entrapped ADA columns using (i) 50% methanol, and (ii) 3% acetic acid. (B) Extraction of EHNA from a sol-gel entrapped ADA column with (i) denaturing 50% methanol, or competitively with (ii) 25 μM adenosine, and (iii) 100 μM adenosine.




Figure S3. Characterization of covalently bound adenosine deaminase monolithic silica columns using separate 10 cm column segments via frontal affinity analysis. Panel (A) depicts the concentration dependent frontal elution time of EHNA compared to the void marker trimethoprim. Panel (B) shows the fit of the FAC equation to the data showing a protein loading (B<sub>T</sub>) of  $712 \pm 17$  pmol and a K<sub>D</sub> of 25  $\pm$  27 nM. The high standard error could be reduced by performing replicate runs using smaller column segments.




Figure S4. Replicate extractions of EHNA from covalently bound ADA column using 3% acetic acid.

### **REFERENCES**

- (1) Hodgson, R. J.; Besanger, T. R.; Brook, M. A.; Brennan, J. D. Anal. Chem. 2005, 77, 7512-7519.
- (2) Ng, E. S. M.; Chan, N. W. C.; Lewis, D. F.; Hindsgaul, O.; Schriemer, D. C. Nat. Protoc. 2007, 2, 1907-1917.
- (3) Murphy, J.; Baker, D. C.; Behling, C.; Turner, R. A. Anal. Biochem. 1982, 122, 328-337.
- (4) Forsberg, E. M.; Green, J. R. A.; Brennan, J. D. Anal. Chem. 2011, 83, 5230-5236.